Sanara MedTech Inc.
For the period ended Dec 31, 2025. Filed Mar 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 24, 2026
SMTI$32.10+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Net Revenue | $103,117,982 | $86,672,425 |
| Cost of goods sold | 7,520,969 | 8,139,901 |
| Gross profit | 95,597,013 | 78,532,524 |
| Operating expenses | ||
| Selling, general and administrative | 78,716,999 | 71,673,642 |
| Research and development | 5,072,483 | 2,828,663 |
| Depreciation and amortization | 2,661,873 | 2,785,829 |
| Change in fair value of earnout liabilities | - | (14,451) |
| Asset impairment charges | 1,841,120 | - |
| Total operating expenses | 88,292,475 | 77,273,683 |
| Operating income | 7,304,538 | 1,258,841 |
| Other income (expense) | ||
| Interest expense | (6,759,800) | (3,128,395) |
| Share of losses from equity method investments | (952,466) | (90,007) |
| Interest income | 3,672 | 21,978 |
| Gain on disposal of property and equipment | 10,932 | - |
| Total other income (expense) | (7,697,662) | (3,196,424) |
| Net loss from continuing operations | (393,124) | (1,937,583) |
| Net loss from discontinued operations (including asset impairment charge of $26,472,407 in 2025) (Note 3) | (37,174,923) | (7,974,315) |
| Net loss | (37,568,047) | (9,911,898) |
| Net loss attributable to noncontrolling interest from continuing operations | (5,441) | (3,224) |
| Net loss attributable to noncontrolling interest from discontinued operations | - | (244,127) |
| Less: Total net loss attributable to noncontrolling interest | (5,441) | (247,351) |
| Net loss attributable to Sanara MedTech shareholders | $(37,562,606) | $(9,664,547) |
| Net loss per share, basic and diluted: | ||
| Continuing operations | $(0.05) | $(0.23) |
| Discontinued operations | (4.31) | (0.91) |
| Net loss per share of common stock, basic and diluted | $(4.36) | $(1.14) |
| Weighted average number of common shares outstanding, basic and diluted | 8,623,028 | 8,484,224 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.